TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximately RMB714 million, a 6.75-fold increase year-on-year. Profit for the year was RMB307 million, while adjusted profit for the year reached approximately RMB356 million, turning a profit compared with the same period last year. Earnings per share were RMB1.41.

According to the announcement, the increase in revenue was mainly attributable to:(i) an increase of RMB622.5 million in licensing income, primarily relating to out-licensing transactions for QX030N and QX031N;(ii) an increase of RMB16.7 million in R&D service income, mainly driven by a RMB35.5 million growth in CDMO services, partially offset by a decrease in clinical service fees for QX004N and QX008N; and(iii) an increase of RMB9 million in the supply of Sailexin , consistent with the growth in sales of Sailexin .

As of now, the Company has one commercialised product, namely Sailexin, the first ustekinumab biosimilar in China, which achieved domestic sales (including VAT) of nearly RMB300 million in 2025.The R&D progress of the two core products is on track.

Oturkibart (奥托奇拜单抗，IL-4Rα monoclonal antibody) has met the primary endpoints in Phase III clinical trials in China for prurigo nodularis (PN) and atopic dermatitis (AD). New Drug Applications (NDAs) for these two indications are expected to be submitted successively within the year. The NDA for Crusekitug (鲁塞奇塔单抗，IL-17A monoclonal antibody) for the treatment of ankylosing spondylitis (AS) has been accepted for review.QX004N (IL-23p19 monoclonal antibody) and QX008N (TSLP monoclonal antibody) are in Phase III clinical trials in China for psoriasis (Ps) and chronic obstructive pulmonary disease (COPD) respectively, with partners accelerating development.As the Company's monoclonal antibody products gradually enter the commercialisation stage, its development prospects remain promising, and the "Qyuns 1.0" layout is nearing completion.

Furthermore, leveraging its profound expertise in the autoimmune field, the Company has efficiently developed a portfolio of long-acting bispecific antibody pipelines. While maintaining its advantages in dermatology, it is actively exploring major potential opportunities in areas such as respiratory diseases. The Company's successive collaborations with Caldera Therapeutics, Roche and Windward Bio demonstrate its execution capability in advancing its global strategy. As QX030N (IL-23p19/TL1A bispecific antibody), QX031N (TSLP/IL-33 bispecific antibody) and QX027N (TSLP/IL-13 bispecific antibody) gradually enter clinical stages, the iteration of "Qyuns 2.0" is underway at full speed.